nach oben

Erschienen in:

26.04.2018 | Übersicht

Respiratory virus-induced heterologous immunity

Part of the problem or part of the solution?

verfasst von: Emanuel Pusch, Harald Renz, Chrysanthi Skevaki, MD PhD

Erschienen in: Allergo Journal | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To provide current knowledge on respiratory virus-induced heterologous immunity (HI) with a focus on humoral and cellular cross-reactivity. Adaptive heterologous immune responses have broad implications on infection, autoimmunity, allergy and transplant immunology. A better understanding of the mechanisms involved might ultimately open up possibilities for disease prevention, for example by vaccination.

Methods

A structured literature search was performed using Medline and PubMed to provide an overview of the current knowledge on respiratory-virus induced adaptive HI.

Results

In HI the immune response towards one antigen results in an alteration of the immune response towards a second antigen. We provide an overview of respiratory virus-induced HI, including viruses such as respiratory syncytial virus (RSV), rhinovirus (RV), coronavirus (CoV) and influenza virus (IV). We discuss T cell receptor (TCR) and humoral cross-reactivity as mechanisms of HI involving those respiratory viruses. Topics covered include HI between respiratory viruses as well as between respiratory viruses and other pathogens. Newly developed vaccines, which have the potential to provide protection against multiple virus strains are also discussed. Furthermore, respiratory viruses have been implicated in the development of autoimmune diseases, such as narcolepsy, Guillain-Barré syndrome, type 1 diabetes or myocarditis. Finally, we discuss the role of respiratory viruses in asthma and the hygiene hypothesis, and review our recent findings on HI between IV and allergens, which leads to protection from experimental asthma.

Conclusion

Respiratory-virus induced HI may have protective but also detrimental effects on the host. Respiratory viral infections contribute to asthma or autoimmune disease development, but on the other hand, a lack of microbial encounter is associated with an increasing number of allergic as well as autoimmune diseases. Future research might help identify the elements which determine a protective or detrimental outcome in HI-based mechanisms.

Fendrick AM, Monto AS, Nightengale B, Sarnes M. The Economic Burden of Non-Influenza-Related Viral Respiratory Tract Infection in the United States. Arch Intern Med 2003;163:487. doi:https://doi.org/10.1001/archinte.163.4.487PubMedCrossRef

Molinari N-AM, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, Weintraub E, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007;25:5086–96. doi:https://doi.org/10.1016/j.vaccine.2007.03.046PubMedCrossRef

Mäkelä MJ, Puhakka T, Ruuskanen O, Leinonen M, Saikku P, Kimpimäki M, et al. Viruses and Bacteria in the Etiology of the Common Cold. J Clin Microbiol 1998;36:539–42PubMedPubMedCentral

Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, et al. Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. N Engl J Med 2015;373:415–27. doi:https://doi.org/10.1056/NEJMoa1500245PubMedCrossRef

Liu L, Oza S, Hogan D, Perin J, Rudan I, Lawn JE, et al. Global, regional, and national causes of child mortality in 2000-13, with projections to inform post-2015 priorities: An updated systematic analysis. The Lancet 2015;385:430–40. doi:https://doi.org/10.1016/S0140-6736(14)61698-6CrossRef

Nair H, Brooks WA, Katz M, Roca A, Berkley JA, Madhi SA, et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. The Lancet 2011;378:1917–30. doi:https://doi.org/10.1016/S0140-6736(11)61051-9CrossRef

Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. The Lancet 2010;375:1545–55. doi:https://doi.org/10.1016/S0140-6736(10)60206-1CrossRef

Wedzicha JA, Seemungal TAR. COPD exacerbations: Defining their cause and prevention. The Lancet 2007;370:786–96. doi:https://doi.org/10.1016/S0140-6736(07)61382-8CrossRef

Jartti T, Gern JE. Role of viral infections in the development and exacerbation of asthma in children. J Allergy Clin Immunol 2017;140:895–906. doi:https://doi.org/10.1016/j.jaci.2017.08.003PubMedCrossRefPubMedCentral

10.

Holt PG, Sly PD. Viral infections and atopy in asthma pathogenesis: new rationales for asthma prevention and treatment. Nature Medicine 2012;18:726–35. doi:https://doi.org/10.1038/nm.2768PubMedCrossRef

11.

Cusick MF, Libbey JE, Fujinami RS. Molecular mimicry as a mechanism of autoimmune disease. Clin Rev Allergy Immunol 2012;42:102–11. doi:https://doi.org/10.1007/s12016-011-8294-7PubMedCrossRef

12.

Netea MG, Quintin J, van der Meer JWM. Trained immunity: a memory for innate host defense. Cell Host Microbe 2011;9:355–61. doi:https://doi.org/10.1016/j.chom.2011.04.006PubMedCrossRef

13.

Goodridge HS, Ahmed SS, Curtis N, Kollmann TR, Levy O, Netea MG, et al. Harnessing the beneficial heterologous effects of vaccination. Nature Reviews Immunology 2016;16:392–400. doi:https://doi.org/10.1038/nri.2016.43PubMedPubMedCentralCrossRef

14.

Martin SF. Adaptation in the innate immune system and heterologous innate immunity. Cell Mol. Life Sci. 2014;71:4115–30. doi:https://doi.org/10.1007/s00018-014-1676-2PubMedCrossRef

15.

Corti D, Bianchi S, Vanzetta F, Minola A, Perez L, Agatic G, et al. Cross-neutralization of four paramyxoviruses by a human monoclonal antibody. Nature 2013;501:439–43 doi:https://doi.org/10.1038/nature12442PubMedCrossRef

16.

D’Orsogna L, van den Heuvel H, van Kooten C, Heidt S, Claas FHJ. Infectious pathogens may trigger specific allo-HLA reactivity via multiple mechanisms. Immunogenetics 2017;69:631–41. doi:https://doi.org/10.1007/s00251-017-0989-3PubMedPubMedCentralCrossRef

17.

Guo H, Topham DJ. Multiple Distinct Forms of CD8+ T Cell Cross-Reactivity and Specificities Revealed after 2009 H1N1 Influenza A Virus Infection in Mice. PLoS ONE 2012;7:1–11. doi:https://doi.org/10.1371/journal.pone.0046166

18.

Sridhar S, Begom S, Bermingham A, Hoschler K, Adamson W, Carman W, et al. Cellular immune correlates of protection against symptomatic pandemic influenza. Nature Medicine 2013;19:1305–12. doi:https://doi.org/10.1038/nm.3350.PubMedCrossRef

19.

Steinke JW, Liu L, Turner RB, Braciale TJ, Borish L. Immune Surveillance by Rhinovirus-Specific Circulating CD4+ and CD8+ T Lymphocytes. PLoS ONE 2015;10:e0115271. doi:https://doi.org/10.1371/journal.pone.0115271PubMedPubMedCentralCrossRef

20.

Wilkinson TM, Li CK, Chui CS, Huang AK, Perkins M, Liebner JC, et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nature Medicine 2012;18:276–82. doi:https://doi.org/10.1038/nm.2612.CrossRef

21.

Acierno PM, Newton DA, Brown EA, Maes L, Baatz JE, Gattoni-Celli S, et al. Cross-reactivity between HLA-A2-restricted FLU-M1:58-66 and HIV p17 GAG:77-85 epitopes in HIV-infected and uninfected individuals. Journal of Translational Medicine 2003;1:3. doi:https://doi.org/10.1186/1479-5876-1-3PubMedPubMedCentralCrossRef

22.

Wedemeyer H, Mizukoshi E, Davis AR, Bennink JR, Rehermann B. Cross-reactivity between hepatitis C virus and Influenza A virus determinant-specific cytotoxic T cells. J Virol 2001;75:11392–400. doi:https://doi.org/10.1128/JVI.75.23.11392PubMedPubMedCentralCrossRef

23.

Su L, Kidd B, Han A, Kotzin J, Davis M. Virus-Specific CD4+ Memory-Phenotype T Cells Are Abundant in Unexposed Adults. Immunity 2013;38:373–83.PubMedPubMedCentralCrossRef

24.

Vujanovic L, Shi J, Kirkwood JM, Storkus WJ, Butterfield LH. Molecular mimicry of MAGE-A6 and Mycoplasma penetrans HF-2 epitopes in the induction of antitumor CD8+ T-cell responses. Oncoimmunology 2014;3:e954501. doi:https://doi.org/10.4161/21624011.2014.954501PubMedPubMedCentralCrossRef

25.

Johnson LR, Weizman O-E, Rapp M, Way SS, Sun JC. Epitope-Specific Vaccination Limits Clonal Expansion of Heterologous Naive T Cells during Viral Challenge. Cell Rep 2016;17:636–44. doi:https://doi.org/10.1016/j.celrep.2016.09.019PubMedPubMedCentralCrossRef

26.

Oberle SG, Hanna-El-Daher L, Chennupati V, Enouz S, Scherer S, Prlic M, Zehn D. A Minimum Epitope Overlap between Infections Strongly Narrows the Emerging T Cell Repertoire. Cell Rep 2016;17:627–35. doi:https://doi.org/10.1016/j.celrep.2016.09.072PubMedPubMedCentralCrossRef

27.

Urbani S, Amadei B, Fisicaro P, Pilli M, Missale G, Bertoletti A, Ferrari C. Heterologous T cell immunity in severe hepatitis C virus infection. J Exp Med 2005;201:675–80. doi:https://doi.org/10.1084/jem.20041058PubMedPubMedCentralCrossRef

28.

Welsh RM, Che JW, Brehm MA, Selin LK. Heterologous immunity between viruses. Immunol Rev 2010;235:244–66. doi:https://doi.org/10.1111/j.0105-2896.2010.00897.xPubMedPubMedCentralCrossRef

29.

Wucherpfennig KW, Strominger JL. Molecular mimicry in T cell-mediated autoimmunity: Viral peptides activate human T cell clones specific for myelin basic protein. Cell 1995;80:695–705. doi:https://doi.org/10.1016/0092-8674(95)90348-8PubMedCrossRefPubMedCentral

30.

Heutinck KM, Yong SL, Tonneijck L, van den Heuvel H, van der Weerd NC, van der Pant KAMI, et al. Virus-Specific CD8(+) T Cells Cross-Reactive to Donor-Alloantigen Are Transiently Present in the Circulation of Kidney Transplant Recipients Infected With CMV and/or EBV. Am J Transplant 2016;16:1480–91. doi:https://doi.org/10.1111/ajt.13618PubMedCrossRef

31.

Younes S-A, Freeman ML, Mudd JC, Shive CL, Reynaldi A, Panigrahi S, et al. IL-15 promotes activation and expansion of CD8+ T cells in HIV-1 infection. J Clin Invest 2016;126:2745–56. doi:https://doi.org/10.1172/JCI85996PubMedPubMedCentralCrossRef

32.

Lertmemongkolchai G, Cai G, Hunter CA, Bancroft GJ. Bystander Activation of CD8+ T Cells Contributes to the Rapid Production of IFN- in Response to Bacterial Pathogens. The Journal of Immunology 2001;166:1097–105. doi:https://doi.org/10.4049/jimmunol.166.2.1097PubMedCrossRef

33.

Kohlmeier JE, Cookenham T, Roberts AD, Miller SC, Woodland DL. Type I interferons regulate cytolytic activity of memory CD8(+) T cells in the lung airways during respiratory virus challenge. Immunity 2010;33:96–105. doi:https://doi.org/10.1016/j.immuni.2010.06.016PubMedPubMedCentralCrossRef

34.

Kamath AT, Sheasby CE, Tough DF. Dendritic Cells and NK Cells Stimulate Bystander T Cell Activation in Response to TLR Agonists through Secretion of IFN- and IFN-. The Journal of Immunology 2005;174:767–76. doi:https://doi.org/10.4049/jimmunol.174.2.767PubMedCrossRef

35.

Chu T, Tyznik AJ, Roepke S, Berkley AM, Woodward-Davis A, Pattacini L, et al. Bystander-activated memory CD8 T cells control early pathogen load in an innate-like, NKG2D-dependent manner. Cell Rep 2013;3:701–8. doi:https://doi.org/10.1016/j.celrep.2013.02.020PubMedPubMedCentralCrossRef

36.

McMaster SR, Wilson JJ, Wang H, Kohlmeier JE. Airway-Resident Memory CD8 T Cells Provide Antigen-Specific Protection against Respiratory Virus Challenge through Rapid IFN-gamma Production. J Immunol 2015;195:203–9. doi:https://doi.org/10.4049/jimmunol.1402975PubMedCrossRef

37.

Jozwik A, Habibi MS, Paras A, Zhu J, Guvenel A, Dhariwal J, et al. RSV-specific airway resident memory CD8+ T cells and differential disease severity after experimental human infection. Nat Commun 2015;6:10224. doi:https://doi.org/10.1038/ncomms10224PubMedCrossRef

38.

Lee Y-N, Lee Y-T, Kim M-C, Gewirtz AT, Kang S-M. A Novel Vaccination Strategy Mediating the Induction of Lung-Resident Memory CD8 T Cells Confers Heterosubtypic Immunity against Future Pandemic Influenza Virus. The Journal of Immunology 2016;196:2637–45. doi:https://doi.org/10.4049/jimmunol.1501637PubMedCrossRef

39.

Zens KD, Chen JK, Farber DL. Vaccine-generated lung tissue-resident memory T cells provide heterosubtypic protection to influenza infection. JCI Insight 2016. doi:https://doi.org/10.1172/jci.insight.85832

40.

Che JW, Selin LK, Welsh RM. Evaluation of non-reciprocal heterologous immunity between unrelated viruses. Virology 2015;482:89–97. doi:https://doi.org/10.1016/j.virol.2015.03.002PubMedCrossRef

41.

Sewell AK. Why must T cells be cross-reactive? Nature reviews. Immunology 2012;12:669–77. doi:https://doi.org/10.1038/nri3279PubMed

42.

Arstila TP. A Direct Estimate of the Human T Cell Receptor Diversity. Science 1999;286:958–61. doi:https://doi.org/10.1126/science.286.5441.958PubMedCrossRef

43.

Mason D. A very high level of crossreactivity is an essential feature of the T-cell receptor. Immunology Today 1998;19:395–404. doi:https://doi.org/10.1016/S0167-5699(98)01299-7PubMedCrossRef

44.

Wooldridge L, Ekeruche-Makinde J, van den Berg HA, Skowera A, Miles JJ, Tan MP, et al. A single autoimmune T cell receptor recognizes more than a million different peptides. J Biol Chem 2012;287:1168–77. doi:https://doi.org/10.1074/jbc.M111.289488PubMedCrossRef

45.

Kagnoff MF, Austin RK, Hubert JJ, Bernardin JE, Kasarda DD. Possible role for a human adenovirus in the pathogenesis of celiac disease. J Exp Med 1984:1544–57

46.

Nilges K, Höhn H, Pilch H, Neukirch C, Freitag K, Talbot PJ, Maeurer MJ. Human papillomavirus type 16 E7 peptide-directed CD8+ T cells from patients with cervical cancer are cross-reactive with the coronavirus NS2 protein. J Virol 2003;77:5464–74. doi:https://doi.org/10.1128/JVI.77.9.5464PubMedPubMedCentralCrossRef

47.

Valkenburg SA, Josephs TM, Clemens EB, Grant EJ, Nguyen THO, Wang GC, et al. Molecular basis for universal HLA-A*0201-restricted CD8+ T-cell immunity against influenza viruses. Proceedings of the National Academy of Sciences 2016;113:4440–5. doi:https://doi.org/10.1073/pnas.1603106113CrossRef

48.

Clute SC, Watkin LB, Cornberg M, Naumov YN, Sullivan JL, Luzuriaga K, et al. Cross-reactive influenza virus-specific CD8+ T cells contribute to lymphoproliferation in Epstein-Barr virus-associated infectious mononucleosis. Journal of Clinical Investigation 2005;115:3602–12 doi:https://doi.org/10.1172/JCI25078PubMedPubMedCentralCrossRef

49.

Cornberg M, Clute SC, Watkin LB, Saccoccio FM, Kim S-K, Naumov YN, et al. CD8 T Cell Cross-Reactivity Networks Mediate Heterologous Immunity in Human EBV and Murine Vaccinia Virus Infections. The Journal of Immunology 2010;184:2825–38. doi:https://doi.org/10.4049/jimmunol.0902168PubMedCrossRef

50.

Markovic-Plese S, Hemmer B, Zhao Y, Simon R, Pinilla C, Martin R. High level of cross-reactivity in influenza virus hemagglutinin-specific CD4+ T-cell response: Implications for the initiation of autoimmune response in multiple sclerosis. J Neuroimmunol 2005;169:31–8. doi:https://doi.org/10.1016/j.jneuroim.2005.07.014PubMedCrossRef

51.

Huckelhoven AG, Etschel JK, Bergmann S, Zitzelsberger K, Mueller-Schmucker SM, Harrer EG, Harrer T. Cross-Reactivity Between Influenza Matrix- and HIV-1 P17-Specific CTL-A Large Cohort Study. J Acquir Immune Defic Syndr 2015;69:528–35. doi:https://doi.org/10.1097/qai.0000000000000657PubMedCrossRef

52.

Ekeruche-Makinde J, Miles JJ, van den Berg HA, Skowera A, Cole DK, Dolton G, et al. Peptide length determines the outcome of TCR/peptide-MHCI engagement. Blood 2013;121:1112–23. doi:https://doi.org/10.1182/blood-2012-06-437202PubMedPubMedCentralCrossRef

53.

Adams JJ, Narayanan S, Birnbaum ME, Sidhu SS, Blevins SJ, Gee MH, et al. Structural interplay between germline interactions and adaptive recognition determines the bandwidth of TCR-peptide-MHC cross-reactivity. Nat Immunol 2016;17:87–94. doi:https://doi.org/10.1038/ni.3310PubMedCrossRef

54.

van Regenmortel MHV. Specificity, polyspecificity, and heterospecificity of antibody-antigen recognition. J Mol Recognit 2014;27:627–39. doi:https://doi.org/10.1002/jmr.2394PubMedCrossRef

55.

Kringelum JV, Nielsen M, Padkjær SB, Lund O. Structural analysis of B-cell epitopes in antibody:protein complexes. Mol Immunol 2013;53:24–34. doi:https://doi.org/10.1016/j.molimm.2012.06.001PubMedCrossRef

56.

Sela-Culang I, Kunik V, Ofran Y. The structural basis of antibody-antigen recognition. Front Immunol 2013

57.

Channappanavar R, Fett C, Zhao J, Meyerholz DK, Perlman S. Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection. J Virol 2014;88:11034–44. doi:https://doi.org/10.1128/JVI.01505-14PubMedPubMedCentralCrossRef

58.

Liu WJ, Zhao M, Liu K, Xu K, Wong G, Tan W, Gao GF. T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV. Antiviral Res. 2017;137:82–92. doi:https://doi.org/10.1016/j.antiviral.2016.11.006PubMedCrossRef

59.

Tai W, Wang Y, Fett CA, Zhao G, Li F, Perlman S, et al. Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants. J Virol 2017. doi:https://doi.org/10.1128/JVI.01651-16

60.

Zhao J, Zhao J, Mangalam AK, Channappanavar R, Fett C, Meyerholz DK, et al. Airway Memory CD4(+) T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses. Immunity 2016;44:1379–91. doi:https://doi.org/10.1016/j.immuni.2016.05.006PubMedPubMedCentralCrossRef

61.

Tu W, Mao H, Zheng J, Liu Y, Chiu SS, Qin G, et al. Cytotoxic T Lymphocytes Established by Seasonal Human Influenza Cross-React against 2009 Pandemic H1N1 Influenza Virus. J Virol 2010;84:6527–35. doi:https://doi.org/10.1128/JVI.00519-10PubMedPubMedCentralCrossRef

62.

Li J, Arévalo MT, Chen Y, Chen S, Zeng M. T-cell-mediated cross-strain protective immunity elicited by prime-boost vaccination with a live attenuated influenza vaccine. International journal of Infectious diseases 2014;27:37–43. doi:https://doi.org/10.1016/j.ijid.2014.05.016PubMedPubMedCentralCrossRef

63.

Mohn KGI, Zhou F, Brokstad KA, Sridhar S, Cox RJ. Boosting of Cross-Reactive and Protection-Associated T Cells in Children After Live Attenuated Influenza Vaccination. J Infect Dis 2017;215:1527–35. doi:https://doi.org/10.1093/infdis/jix165PubMedPubMedCentralCrossRef

64.

Magini D, Giovani C, Mangiavacchi S, Maccari S, Cecchi R, Ulmer JB, et al. Self-Amplifying mRNA Vaccines Expressing Multiple Conserved Influenza Antigens Confer Protection against Homologous and Heterosubtypic Viral Challenge. PLoS ONE 2016;11:e0161193. doi:https://doi.org/10.1371/journal.pone.0161193PubMedPubMedCentralCrossRef

65.

Chua BY, Wong CY, Mifsud EJ, Edenborough KM, Sekiya T, Tan ACL, et al. Inactivated influenza vaccine that provides rapid, innate-immune- system-mediated protection and subsequent long-term adaptive immunity. mBio 2015;6:1–11. doi:https://doi.org/10.1128/mBio.01024-15CrossRef

66.

Krammer F, Palese P. Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr Opin Virol 2013;3:521–30. doi:https://doi.org/10.1016/j.coviro.2013.07.007PubMedPubMedCentralCrossRef

67.

Ellebedy AH, Krammer F, Li G-M, Miller MS, Chiu C, Wrammert J, et al. Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans. Proc Natl Acad Sci U S A 2014;111:13133–8. doi:https://doi.org/10.1073/pnas.1414070111PubMedPubMedCentralCrossRef

68.

Krammer F. Novel universal influenza virus vaccine approaches. Curr Opin Virol 2016;17:95–103. doi:https://doi.org/10.1016/j.coviro.2016.02.002PubMedPubMedCentralCrossRef

69.

Carter DM, Darby CA, Lefoley BC, Crevar CJ, Alefantis T, Oomen R, et al. Design and Characterization of a Computationally Optimized Broadly Reactive Hemagglutinin Vaccine for H1N1 Influenza Viruses. J Virol 2016;90:4720–34. doi:https://doi.org/10.1128/JVI.03152-15PubMedPubMedCentralCrossRef

70.

Deng L, Cho KJ, Fiers W, Saelens X. M2e-Based Universal Influenza A Vaccines. Vaccines (Basel) 2015;3:105–36. doi:https://doi.org/10.3390/vaccines3010105CrossRef

71.

Eliasson DG, Omokanye A, Schön K, Wenzel UA, Bernasconi V, Bemark M, et al. M2e-tetramer-specific memory CD4 T cells are broadly protective against influenza infection. Mucosal Immunology 2017:EP -. doi:https://doi.org/10.1038/mi.2017.14

72.

Schotsaert M, Ysenbaert T, Smet A, Schepens B, Vanderschaeghe D, Stegalkina S, et al. Long-Lasting Cross-Protection Against Influenza A by Neuraminidase and M2e-based immunization strategies. Nature Scientific Reports 2016. doi:https://doi.org/10.1038/srep24402

73.

Ramos EL, Mitcham JL, Koller TD, Bonavia A, Usner DW, Balaratnam G, et al. Efficacy and safety of treatment with an anti-m2e monoclonal antibody in experimental human influenza. J Infect Dis 2015;211:1038–44. doi:https://doi.org/10.1093/infdis/jiu539PubMedCrossRef

74.

Graham BS. Vaccines against respiratory syncytial virus: The time has finally come. Vaccine 2016;34:3535–41. doi:https://doi.org/10.1016/j.vaccine.2016.04.083PubMedPubMedCentralCrossRef

75.

Cortjens B, Yasuda E, Yu X, Wagner K, Claassen YB, Bakker AQ, et al. Broadly Reactive Anti-Respiratory Syncytial Virus G Antibodies from Exposed Individuals Effectively Inhibit Infection of Primary Airway Epithelial Cells. J Virol 2017. doi:https://doi.org/10.1128/JVI.02357-16

76.

Lee J-Y, Chang J. Universal vaccine against respiratory syncytial virus A and B subtypes. PLoS ONE. 2017;12:e0175384. doi:https://doi.org/10.1371/journal.pone.0175384PubMedPubMedCentralCrossRef

77.

Taylor G, Thom M, Capone S, Pierantoni A, Guzman E, Herbert R, et al. Efficacy of a virus-vectored vaccine against human and bovine respiratory syncytial virus infections. Sci Transl Med. 2015;7:300ra127. doi:https://doi.org/10.1126/scitranslmed.aac5757PubMedCrossRef

78.

Schuster JE, Cox RG, Hastings AK, Boyd KL, Wadia J, Chen Z, et al. A broadly neutralizing human monoclonal antibody exhibits in vivo efficacy against both human metapneumovirus and respiratory syncytial virus. J Infect Dis. 2015;211:216–25. doi:https://doi.org/10.1093/infdis/jiu307PubMedCrossRef

79.

Glanville N, Mclean GR, Guy B, Lecouturier V, Berry C, Girerd Y, et al. Cross-Serotype Immunity Induced by Immunization with a Conserved Rhinovirus Capsid Protein. PLoS Pathogens. 2013;9:e1003669. doi:https://doi.org/10.1371/journal.ppat.1003669PubMedPubMedCentralCrossRef

80.

Muehling LM, Mai DT, Kwok WW, Heymann PW, Pomes A, Woodfolk JA. Circulating Memory CD4+ T Cells Target Conserved Epitopes of Rhinovirus Capsid Proteins and Respond Rapidly to Experimental Infection in Humans. J Immunol. 2016;197:3214–24. doi:https://doi.org/10.4049/jimmunol.1600663PubMedCrossRef

81.

Iwasaki J, Smith W-A, Stone SR, Thomas WR, Hales BJ. Species-specific and cross-reactive IgG1 antibody binding to viral capsid protein 1 (VP1) antigens of human rhinovirus species A, B and C. PLoS ONE. 2013;8:e70552. doi:https://doi.org/10.1371/journal.pone.0070552PubMedPubMedCentralCrossRef

82.

Niespodziana K, Napora K, Cabauatan C, Focke-Tejkl M, Keller W, Niederberger V, et al. Misdirected antibody responses against an N-terminal epitope on human rhinovirus VP1 as explanation for recurrent RV infections. FASEB J. 2012;26:1001–8. doi:https://doi.org/10.1096/fj.11-193557PubMedCrossRef

83.

Aslan N, Watkin LB, Gil A, Mishra R, Clark FG, Welsh RM, et al. Severity of Acute Infectious Mononucleosis Correlates with Cross-Reactive Influenza CD8 T-Cell Receptor Repertoires. mBio 2017. doi:https://doi.org/10.1128/mBio.01841-17

84.

Odumade OA, Knight JA, Schmeling DO, Masopust D, Balfour HH, JR, Hogquist KA. Primary Epstein-Barr virus infection does not erode preexisting CD8(+) T cell memory in humans. J Exp Med. 2012;209:471–8. doi:https://doi.org/10.1084/jem.20112401PubMedPubMedCentralCrossRef

85.

Watkin LB, Mishra R, Gil A, Aslan N, Ghersi D, Luzuriaga K, Selin LK. Unique influenza A cross-reactive memory CD8 T-cell receptor repertoire has a potential to protect against EBV seroconversion. Journal of Allergy and Clinical Immunology. 2017;140:1206–10. doi:https://doi.org/10.1016/j.jaci.2017.05.037PubMedCrossRef

86.

Zhang S, Bakshi RK, Suneetha PV, Fytili P, Antunes DA, Vieira GF, et al. Frequency, Private Specificity, and Cross-Reactivity of Preexisting Hepatitis C Virus (HCV)-Specific CD8+ T Cells in HCV-Seronegative Individuals: Implications for Vaccine Responses. J Virol. 2015;89:8304–17. doi:https://doi.org/10.1128/JVI.00539-15PubMedPubMedCentralCrossRef

87.

Kasprowicz V, Ward SM, Turner A, Grammatikos A, Nolan BE, Lewis-ximenez L, et al. Defining the directionality and quality of influenza virus - specific CD8 + T cell cross-reactivity in individuals infected with hepatitis C virus. Journal of Clinical Investigation. 2008;118:1143–53. doi:https://doi.org/10.1172/JCI33082DS1PubMedPubMedCentral

88.

Ertl HC. Viral vectors as vaccine carriers. Curr Opin Virol. 2016;17:1–8. doi:https://doi.org/10.1016/j.coviro.2016.06.001CrossRef

89.

Kotterman MA, Chalberg TW, Schaffer DV. Viral Vectors for Gene Therapy: Translational and Clinical Outlook. Annu. Rev. Biomed. Eng. 2015;17:63–89. doi:https://doi.org/10.1146/annurev-bioeng-071813-104938PubMedCrossRef

90.

Singh S, Vedi S, Samrat SK, Li W, Kumar R, Agrawal B. Heterologous immunity between adenoviruses and hepatitis C virus: A new paradigm in HCV immunity and vaccines. PLoS ONE. 2016;11:1–23. doi:https://doi.org/10.1371/journal.pone.0146404

91.

Frahm N, DeCamp AC, Friedrich DP, Carter DK, Defawe OD, Kublin JG, et al. Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine. J Clin Invest 2012;122:359–67. doi:https://doi.org/10.1172/JCI60202PubMedCrossRef

92.

Pennington SH, Thompson AL, Wright AKA, Ferreira DM, Jambo KC, Wright AD, et al. Oral Typhoid Vaccination With Live-Attenuated Salmonella Typhi Strain Ty21a Generates Ty21a-Responsive and Heterologous Influenza Virus-Responsive CD4 + and CD8 + T Cells at the Human Intestinal Mucosa. Journal of Infectious Diseases 2016;213:1809–19. doi:https://doi.org/10.1093/infdis/jiw030PubMedPubMedCentralCrossRef

93.

Tenembaum S, Chitnis T, Ness J, Hahn JS. Acute disseminated encephalomyelitis. Neurology 2007:23–3

94.

Karussis D, Petrou P. The spectrum of post-vaccination inflammatory CNS demyelinating syndromes}. Autoimmun Rev 2014;13:215–24. doi:https://doi.org/10.1016/j.autrev.2013.10.003PubMedCrossRef

95.

Ravaglia S, Ceroni M, Moglia A, Todeschini A, Marchioni E. Post-infectious and post-vaccinal acute disseminated encephalomyelitis occurring in the same patients. J Neurol 2004;251:1147–50. doi:https://doi.org/10.1007/s00415-004-0498-9PubMedCrossRef

96.

Athauda D, Andrews TC, Holmes PA, Howard RS. Multiphasic acute disseminated encephalomyelitis (ADEM) following influenza type A (swine specific H1N1). J Neurol 2012;259:775–8. doi:https://doi.org/10.1007/s00415-011-6258-8PubMedCrossRef

97.

Au WY, Lie AKW, Cheung RTF, Cheng PW, Ooi CGC, Yujenc K-Y, Kwong Y-L. Acute disseminated encephalomyelitis after para-influenza infection post bone marrow transplantation. Leuk Lymphoma 2002;43:455–7. doi:https://doi.org/10.1080/10428190290006350PubMedCrossRef

98.

Sellers SA, Hagan RS, Hayden FG, Fischer WA. The hidden burden of influenza: A review of the extra-pulmonary complications of influenza infection. Influenza Other Respir Viruses 2017;11:372–93. doi:https://doi.org/10.1111/irv.12470PubMedPubMedCentralCrossRef

99.

Blackmore S, Hernandez J, Juda M, Ryder E, Freund GG, Johnson RW, Steelman AJ. Influenza infection triggers disease in a genetic model of experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 2017;114:E6107–E6116. doi:https://doi.org/10.1073/pnas.1620415114PubMedPubMedCentralCrossRef

100.

Chen Q, Liu Y, Lu A, Ni K, Xiang Z, Wen K, Tu W. Influenza virus infection exacerbates experimental autoimmune encephalomyelitis disease by promoting type I T cells infiltration into central nervous system. J Autoimmun 2017;77:1–10. doi:https://doi.org/10.1016/j.jaut.2016.10.006PubMedCrossRef

101.

Sriram S, Steiner I. Experimental allergic encephalomyelitis: A misleading model of multiple sclerosis. Ann Neurol. 2005;58:939–45. doi:https://doi.org/10.1002/ana.20743.PubMedCrossRef

102.

Pohl-Koppe A, Burchett SK, Thiele EA, Hafler DA. Myelin basic protein reactive Th2 T cells are found in acute disseminated encephalomyelitis. J Neuroimmunol 1998;91:19–27. doi:https://doi.org/10.1016/S0165-5728(98)00125-8PubMedCrossRef

103.

Hennes E-M, Baumann M, Schanda K, Anlar B, Bajer-Kornek B, Blaschek A, et al. Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome. Neurology. 2017;89:900–8. doi:https://doi.org/10.1212/WNL.0000000000004312PubMedCrossRef

104.

Boucher A, Desforges M, Duquette P, Talbot PJ. Long-term human coronavirus-myelin cross-reactive T-cell clones derived from multiple sclerosis patients. Clin Immunol 2007;123:258–67. doi:https://doi.org/10.1016/j.clim.2007.02.002PubMedCrossRefPubMedCentral

105.

Peschl P, Bradl M, Höftberger R, Berger T, Reindl M. Myelin Oligodendrocyte Glycoprotein: Deciphering a Target in Inflammatory Demyelinating Diseases. Front Immunol 2017;8:529. doi:https://doi.org/10.3389/fimmu.2017.00529PubMedPubMedCentralCrossRef

106.

Lehmann HC, Hartung H-P, Kieseier BC, Hughes RA. Guillain-Barré syndrome after exposure to influenza virus. Lancet Infectious Diseases 2010;10:643–51PubMedCrossRef

107.

Martín Arias LH, Sanz R, Sáinz M, Treceño C, Carvajal A. Guillain-Barré syndrome and influenza vaccines: A meta-analysis. Vaccine 2015;33:3773–8. doi:https://doi.org/10.1016/j.vaccine.2015.05.013PubMedCrossRef

108.

Nachamkin I, Shadomy SV, Moran AP, Cox N, Fitzgerald C, Ung H, et al. Anti-ganglioside antibody induction by swine (A/NJ/1976/H1N1) and other influenza vaccines: insights into vaccine-associated Guillain-Barré syndrome. J Infect Dis 2008;198:226–33. doi:https://doi.org/10.1086/589624PubMedCrossRef

109.

Partinen M, Kornum BR, Plazzi G, Jennum P, Julkunen I, Vaarala O. Narcolepsy as an autoimmune disease: The role of H1N1 infection and vaccination. The Lancet Neurology 2014;13:600–13. doi:https://doi.org/10.1016/S1474-4422(14)70075-4PubMedCrossRef

110.

Han F, Lin L, Warby SC, Faraco J, Li J, Dong SX, et al. Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. Ann Neurol 2011;70:410–7. doi:https://doi.org/10.1002/ana.22587PubMedCrossRef

111.

Ahmed SS, Volkmuth W, Duca J, Corti L, Pallaoro M, Pezzicoli A, et al. Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2. Sci Transl Med 2015;7:294ra105. doi:https://doi.org/10.1126/scitranslmed.aab2354PubMedCrossRef

112.

Saariaho A-H, Vuorela A, Freitag TL, Pizza F, Plazzi G, Partinen M, et al. Autoantibodies against ganglioside GM3 are associated with narcolepsy-cataplexy developing after Pandemrix vaccination against 2009 pandemic H1N1 type influenza virus. J Autoimmun 2015;63:68–75. doi:https://doi.org/10.1016/j.jaut.2015.07.006PubMedCrossRef

113.

Cvetkovic-Lopes V, Bayer L, Dorsaz S, Maret S, Pradervand S, Dauvilliers Y, et al. Elevated Tribbles homolog 2-specific antibody levels in narcolepsy patients. J Clin Invest 2010;120:713–9. doi:https://doi.org/10.1172/JCI41366PubMedPubMedCentralCrossRef

114.

Lind A, Ramelius A, Olsson T, Arnheim-Dahlström L, Lamb F, Khademi M, et al. A/H1N1 antibodies and TRIB2 autoantibodies in narcolepsy patients diagnosed in conjunction with the Pandemrix vaccination campaign in Sweden 2009-2010. J Autoimmun 2014;50:99–106. doi:https://doi.org/10.1016/j.jaut.2014.01.031PubMedCrossRef

115.

Katzav A, Arango MT, Kivity S, Tanaka S, Givaty G, Agmon-Levin N, et al. Passive transfer of narcolepsy: anti-TRIB2 autoantibody positive patient IgG causes hypothalamic orexin neuron loss and sleep attacks in mice. J Autoimmun 2013;45:24–30. doi:https://doi.org/10.1016/j.jaut.2013.06.010PubMedCrossRef

116.

Prüss H, Finke C, Höltje M, Hofmann J, Klingbeil C, Probst C, et al. N-methyl-D-aspartate receptor antibodies in herpes simplex encephalitis. Ann Neurol 2012;72:902–11. doi:https://doi.org/10.1002/ana.23689PubMedPubMedCentralCrossRef

117.

Berger B, Pytlik M, Hottenrott T, Stich O. Absent anti-N-methyl-D-aspartate receptor NR1a antibodies in herpes simplex virus encephalitis and varicella zoster virus infections. Int J Neurosci 2017;127:109–17. doi:https://doi.org/10.3109/00207454.2016.1147447PubMedCrossRef

118.

Brown AS. Epidemiologic studies of exposure to prenatal infection and risk of schizophrenia and autism. Dev Neurobiol 2012;72:1272–6. doi:https://doi.org/10.1002/dneu.22024PubMedPubMedCentralCrossRef

119.

Lucchese G, Capone G, Kanduc D. Peptide sharing between influenza A H1N1 hemagglutinin and human axon guidance proteins. Schizophr Bull 2014;40:362–75. doi:https://doi.org/10.1093/schbul/sbs197PubMedCrossRef

120.

Lucchese G. Understanding Neuropsychiatric Diseases, Analyzing the Peptide Sharing between Infectious Agents and the Language-Associated NMDA 2A Protein. Front Psychiatry 2016;7:60. doi:https://doi.org/10.3389/fpsyt.2016.00060PubMedPubMedCentralCrossRef

121.

Wheatland R. Chronic ACTH autoantibodies are a significant pathological factor in the disruption of the hypothalamic-pituitary-adrenal axis in chronic fatigue syndrome, anorexia nervosa and major depression. Med Hypotheses 2005;65:287–95. doi:https://doi.org/10.1016/j.mehy.2005.02.031PubMedCrossRef

122.

Wheatland R. Molecular mimicry of ACTH in SARS - implications for corticosteroid treatment and prophylaxis. Med Hypotheses 2004;63:855–62. doi:https://doi.org/10.1016/j.mehy.2004.04.009PubMedCrossRefPubMedCentral

123.

Beyerlein A, Donnachie E, Ziegler A-G. Infections in early Life and development of celiac disease. Am J Epidemiol 2017. doi:https://doi.org/10.1093/aje/kwx190

124.

KAGNOFF MF, PATERSON YJ, KUMAR PJ, KASARDA DD, CARBONE FR, UNSWORTH DJ, AUSTIN RK. Evidence for the role of a human intestinal adenovirus in the pathogenesis of coeliac disease. Gut 1987;28:995–1001PubMedPubMedCentralCrossRef

125.

Mantzaris GJ, Karagiannis JA, Priddle JD, Jewell DP. Cellular hypersensitivity to a synthetic dodecapeptide derived from human adenovirus 12 which resembles a sequence of A-gliadin in patients with coeliac disease. Gut 1990;31:668–73PubMedPubMedCentralCrossRef

126.

Kupfer SS, Jabri B. Pathophysiology of celiac disease. Gastrointest Endosc Clin N Am 2012;22:639–60. doi:https://doi.org/10.1016/j.giec.2012.07.003PubMedCrossRef

127.

Caforio ALP, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013;34:2636–48, 2648a-2648d. doi:https://doi.org/10.1093/eurheartj/eht210PubMedCrossRef

128.

Massilamany C, Gangaplara A, Steffen D, Reddy J. Identification of novel mimicry epitopes for cardiac myosin heavy chain-? that induce autoimmune myocarditis in A/J mice. Cell Immunol 2011;271:438–49. doi:https://doi.org/10.1016/j.cellimm.2011.08.013PubMedCrossRef

129.

Gangaplara A, Massilamany C, Brown DM, Delhon G, Pattnaik AK, Chapman N, et al. Coxsackievirus B3 infection leads to the generation of cardiac myosin heavy chain-α-reactive CD4 T cells in A/J mice. Clin Immunol 2012;144:237–49. doi:https://doi.org/10.1016/j.clim.2012.07.003PubMedCrossRef

130.

Root-Bernstein R. Rethinking Molecular Mimicry in Rheumatic Heart Disease and Autoimmune Myocarditis: Laminin, Collagen IV, CAR, and B1AR as Initial Targets of Disease. Front Pediatr 2014;2:85. doi:https://doi.org/10.3389/fped.2014.00085PubMedPubMedCentralCrossRef

131.

Igoe A, Scofield RH. Autoimmunity and infection in Sjögren’s syndrome. Curr Opin Rheumatol 2013;25:480–7. doi:https://doi.org/10.1097/BOR.0b013e32836200d2PubMedPubMedCentralCrossRef

132.

Tong L, Koh V, Thong BY-H. Review of autoantigens in Sjögren’s syndrome: An update. J Inflamm Res 2017;10:97–105. doi:https://doi.org/10.2147/JIR.S137024PubMedPubMedCentralCrossRef

133.

Singh N, Cohen PL. The T cell in Sjogren’s syndrome: Force majeure, not spectateur. J Autoimmun 2012;39:229–33. doi:https://doi.org/10.1016/j.jaut.2012.05.019PubMedPubMedCentralCrossRef

134.

Stathopoulou EA, Routsias JG, Stea EA, Moutsopoulos HM, Tzioufas AG. Cross-reaction between antibodies to the major epitope of Ro60 kD autoantigen and a homologous peptide of Coxsackie virus 2B protein. Clin Exp Immunol 2005;141:148–54. doi:https://doi.org/10.1111/j.1365-2249.2005.02812.xPubMedPubMedCentralCrossRef

135.

Szymula A, Rosenthal J, Szczerba BM, Bagavant H, Fu SM, Deshmukh US. T cell epitope mimicry between Sjögren’s syndrome Antigen A (SSA)/Ro60 and oral, gut, skin and vaginal bacteria. Clin Immunol 2014;152:1–9. doi:https://doi.org/10.1016/j.clim.2014.02.004PubMedPubMedCentralCrossRef

136.

Lönnrot M, Lynch KF, Elding Larsson H, Lernmark Å, Rewers MJ, Törn C, et al. Respiratory infections are temporally associated with initiation of type 1 diabetes autoimmunity: The TEDDY study. Diabetologia 2017 doi:https://doi.org/10.1007/s00125-017-4365-5

137.

Beeck A op de, Eizirik DL. Viral infections in type 1 diabetes mellitus—why the β cells? Nature Reviews Endocrinology 2016;12:263–73. doi:https://doi.org/10.1038/nrendo.2016.30PubMedCentralCrossRef

138.

Hiemstra HS, Schloot NC, van Rood JJ, Willemen SJM, Franken KLMC, de Vries RRP, et al. Cytomegalovirus in autoimmunity: T cell crossreactivity to viral antigen and autoantigen glutamic acid decarboxylase. Proc Natl Acad Sci U S A 2001;98:3988–91PubMedPubMedCentralCrossRef

139.

Honeyman MC, Stone NL, Falk BA, Nepom G, Harrison LC. Evidence for molecular mimicry between human T cell epitopes in rotavirus and pancreatic islet autoantigens. J Immunol 2010;184:2204–10. doi:https://doi.org/10.4049/jimmunol.0900709PubMedCrossRef

140.

Qi Z, Hu H, Wang Z, Wang G, Li Y, Zhao X, et al. Antibodies against H1N1 influenza virus cross-react with ?-cells of pancreatic islets. J Diabetes Investig 2017. doi:https://doi.org/10.1111/jdi.12690

141.

Thorel F, Népote V, Avril I, Kohno K, Desgraz R, Chera S, Herrera PL. Conversion of adult pancreatic alpha-cells to beta-cells after extreme beta-cell loss. Nature 2010;464:1149–54. doi:https://doi.org/10.1038/nature08894PubMedPubMedCentralCrossRef

142.

Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: Executive summary of the GINA Dissemination Committee report. Allergy 2004;59:469–78. doi:https://doi.org/10.1111/j.1398-9995.2004.00526.xPubMedCrossRef

143.

Lötvall J, Pawankar R, Wallace DV, Akdis CA, Rosenwasser LJ, Weber RW, et al. We Call for iCAALL: International Collaboration in Asthma, Allergy and Immunology. The World Allergy Organization Journal 2012;5:39–40. doi:https://doi.org/10.1097/WOX.0b013e3182504245PubMedPubMedCentralCrossRef

144.

Papadopoulos NG, Christodoulou I, Rohde G, Agache I, Almqvist C, Bruno A, et al. Viruses and bacteria in acute asthma exacerbations—a GA² LEN-DARE systematic review. Allergy 2011;66:458–68. doi:https://doi.org/10.1111/j.1398-9995.2010.02505.xPubMedCrossRef

145.

Lukkarinen M, Koistinen A, Turunen R, Lehtinen P, Vuorinen T, Jartti T. Rhinovirus-induced first wheezing episode predicts atopic but not nonatopic asthma at school age. J Allergy Clin Immunol 2017;140:988–95. doi:https://doi.org/10.1016/j.jaci.2016.12.991PubMedCrossRefPubMedCentral

146.

Jackson DJ, Gangnon RE, Evans MD, Roberg KA, Anderson EL, Pappas TE, et al. Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children. Am J Respir Crit Care Med 2008;178:667–72. doi:https://doi.org/10.1164/rccm.200802-309OCPubMedPubMedCentralCrossRef

147.

Strachan DP. Hay fever, hygiene, and household size. BMJ 1989;299:1259–60. doi:https://doi.org/10.1136/bmj.299.6710.1259PubMedPubMedCentralCrossRef

148.

Garn H, Renz H. Epidemiological and immunological evidence for the hygiene hypothesis. Immunobiology 2007;212:441–52. doi:https://doi.org/10.1016/j.imbio.2007.03.006PubMedCrossRef

149.

Bénédicte Machiels, Mickael Dourcy, Xue Xiao, Justine Javaux, Claire Mesnil, Catherine Sabatel, et al. A gammaherpesvirus provides protection against allergic asthma by inducing the replacement of resident alveolar macrophages with regulatory monocytes. Nat Immunol 2017;18:1310–20PubMedCrossRef

150.

Chang Y-J, Kim HY, Albacker LA, Lee HH, Baumgarth N, Akira S, et al. Influenza infection in suckling mice expands an NKT cell subset that protects against airway hyperreactivity. J Clin Invest 2011;121:57–69. doi:https://doi.org/10.1172/JCI44845PubMedCrossRef

151.

Conrad ML, Ferstl R, Teich R, Brand S, Blümer N, Yildirim AO, et al. Maternal TLR signaling is required for prenatal asthma protection by the nonpathogenic microbe Acinetobacter lwoffii F78. J Exp Med 2009;206:2869–77. doi:https://doi.org/10.1084/jem.20090845PubMedPubMedCentralCrossRef

152.

Wohlleben G, Muller J, Tatsch U, Hambrecht C, Herz U, Renz H, et al. Influenza A Virus Infection Inhibits the Efficient Recruitment of Th2 Cells into the Airways and the Development of Airway Eosinophilia. J Immunol 2003;170:4601–11. doi:https://doi.org/10.4049/jimmunol.170.9.4601PubMedCrossRef

153.

Skevaki C, Hudemann C, Matrosovich M, Möbs C, Paul S, Wachtendorf A, et al. Influenza-derived peptides cross-react with allergens and provide asthma protection. J Allergy Clin Immunol 2017. doi:https://doi.org/10.1016/j.jaci.2017.07.056. [Epub ahead of print]

154.

Bien CG, Bauer J. Autoimmune epilepsies. Neurotherapeutics 2014;11:311–8. doi:https://doi.org/10.1007/s13311-014-0264-3PubMedPubMedCentralCrossRef

155.

Mustalahti K, Catassi C, Reunanen A, Fabiani E, Heier M, McMillan S, et al. The prevalence of celiac disease in Europe: results of a centralized, international mass screening project. Ann Med 2010;42:587–95. doi:https://doi.org/10.3109/07853890.2010.505931PubMedCrossRef

156.

Lerner A, Arleevskaya M, Schmiedl A, Matthias T. Microbes and Viruses Are Bugging the Gut in Celiac Disease. Are They Friends or Foes? Front Microbiol 2017;8:1392. doi:https://doi.org/10.3389/fmicb.2017.01392PubMedPubMedCentralCrossRef

Titel: Respiratory virus-induced heterologous immunity
Part of the problem or part of the solution?
verfasst von: Emanuel Pusch
Harald Renz
Chrysanthi Skevaki, MD PhD
Publikationsdatum: 26.04.2018
Verlag: Springer Medizin
Erschienen in: Allergo Journal / Ausgabe 3/2018
Print ISSN: 0941-8849
Elektronische ISSN: 2195-6405
DOI: https://doi.org/10.1007/s15007-018-1580-4

Neu im Fachgebiet HNO

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

29.05.2024 Hörstörungen Nachrichten

Hört jemand im Alter schlecht, nimmt das Hirn- und Hippocampusvolumen besonders schnell ab, was auch mit einem beschleunigten kognitiven Abbau einhergeht. Und diese Prozesse scheinen sich unabhängig von der Amyloidablagerung zu ereignen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2018

Allergiekongress in Dresden — Bilanz, Fortschritte und Visionen

Anaphylaxie nach Hundertfüßerbiss

Reif für die Insel!

Neue SCIT bei Schimmelpilzallergie: Aufdosierung in drei Schritten und zwei Wochen